What is the risk of permanent disability from a multiple sclerosis relapse?
OBJECTIVE
To determine how often patients with relapsing-remitting multiple sclerosis (MS) develop severe (Expanded Disability Status Scale [EDSS] > or =6.0) sustained (greater than 6 months) disability due to an acute relapse.


METHODS
We analyzed our database of all patients with MS followed up at the Marshfield Multiple Sclerosis Center.


RESULTS
Among the 1,078 patients, there were 2,587 relapses (mean of 2.4 per patient, with a range of 1-11 attacks over 1-15 years). Only 7 patients had a relapse resulting in EDSS > or =6 that did not recover. Genetic analysis showed no difference in HLA-DR or NOS2A loci between these patients and other MS populations, nor were there any clinical factors that identified high risk. Two of these patients were on interferon treatment at the time of their disabling attack.


CONCLUSIONS
The fear of a sudden irreversible disability should not influence therapeutic decisions because such attacks are very rare and can occur whether or not patients are treated with interferons.
Department of Neurology, Marshfield Clinic, Marshfield, WI 54449, USA.
Khemissa
K
Bejaoui
Loren A
LA
Rolak
D000203:Activities of Daily Living; D000328:Adult; D016208:Databases, Factual; D004185:Disability Evaluation; D005260:Female; D005838:Genotype; D006684:HLA-DR Antigens / Q000235:genetics; D059811:HLA-DRB1 Chains; D006801:Humans; D008297:Male; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000453:epidemiology* / Q000235:genetics; D052247:Nitric Oxide Synthase Type II / Q000235:genetics; D016133:Polymerase Chain Reaction; D012008:Recurrence; D012306:Risk; D012720:Severity of Illness Index
D006684:HLA-DR Antigens; D059811:HLA-DRB1 Chains; C496319:NOS2 protein, human; D052247:Nitric Oxide Synthase Type II